While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments. The transaction adds a pipeline of early-stage drug ...